Related Experiment Video
Updated: Aug 5, 2026
16:04
A Tetracycline-regulated Cell Line Produces High-titer Lentiviral Vectors that Specifically Target Dendritic Cells
Published on: June 19, 2013
Recombinant Sendai virus vectors for activated T lymphocytes
S Okano1, Y Yonemitsu, S Nagata
1Division of Pathophygiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Gene Therapy
|July 29, 2003
Summary
Sendai virus vectors (SeV) efficiently deliver genes into activated T-lymphocytes for immunological disorder treatment. This novel gene therapy approach overcomes low efficiency seen with other methods, offering a promising clinical alternative.
Area of Science:
- Immunology
- Gene Therapy
- Virology
Background:
- T-lymphocyte gene therapy shows promise for immunological disorders.
- Current limitations include low gene transfer efficiency, hindering therapeutic potential.
Purpose of the Study:
- To evaluate the efficiency and specificity of a recombinant Sendai virus vector (SeV) for T-lymphocyte gene transfer.
- To explore SeV as a potential solution for improving gene therapy efficacy in T cells.
Main Methods:
- Utilized a recombinant Sendai virus vector (SeV) carrying the enhanced green fluorescent protein (EGFP) gene.
- Tested transduction efficiency in activated and naive murine and human T cells.
- Investigated SeV's tropism and potential mechanisms for selective gene transfer.
Main Results:
- SeV efficiently transduced and expressed foreign genes in activated T cells, but not naive T cells.
- Gene transfer occurred without complex procedures like centrifugation or specific reagents.
- Transduction was selective for antigen-activated T cells, avoiding bystander activation effects.
- Receptor saturation studies suggested SeV entry is restricted in naive T cells.
Conclusions:
- Recombinant SeV vectors demonstrate high efficiency and specificity for gene transfer into activated T cells.
- SeV offers a potentially superior alternative to traditional viral vectors like retroviruses in T-cell gene therapy.
- This SeV vector system presents a promising advancement for clinical applications in T-cell-directed gene therapy.
